v3.25.4
Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Statement of Comprehensive Income [Abstract]      
Net income before allocation to noncontrolling interests $ 7,812 $ 8,062 $ 2,158
Foreign currency translation adjustments, net (181) 32 452
Unrealized holding gains/(losses) on derivative financial instruments, net (212) 499 626
Reclassification adjustments for (gains)/losses included in net income [1] (269) (159) (413)
Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total (481) 341 213
Unrealized holding gains/(losses) on available-for-sale securities, net 97 (152) (121)
Reclassification adjustments for (gains)/losses included in net income [2] (7) 42 (141)
Other comprehensive income (loss), available-for-sale securities adjustment, before tax, total 89 (111) (261)
Benefit plans: prior service (costs)/credits and other, net (16) 193 (25)
Reclassification adjustments related to amortization of prior service costs and other, net (84) (109) (117)
Reclassification adjustments related to curtailments of prior service costs and other, net (52) 0 (15)
Other comprehensive income (loss), benefit plans, prior service (costs)/credits, before tax, total (152) 84 (157)
Other comprehensive income/(loss), before tax (725) 347 246
Tax provision/(benefit) on other comprehensive income/(loss) (486) 231 (85)
Other comprehensive income/(loss) before allocation to noncontrolling interests (239) 116 331
Comprehensive income/(loss) before allocation to noncontrolling interests 7,573 8,178 2,488
Less: Comprehensive income/(loss) attributable to noncontrolling interests 29 28 26
Comprehensive income/(loss) attributable to Pfizer Inc. $ 7,544 $ 8,149 $ 2,462
[1] Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.
[2] Reclassified into Other (income)/deductions—net.